1887

Abstract

In this pilot study, the in vitro antimicrobial activity of iclaprim, a diaminopyrimidine, tested in combination with other antimicrobials against recent and common Gram-positive and Gram-negative respiratory pathogens, was examined by the checkerboard method. The range of minimal inhibitory concentrations (MICs) for iclaprim against all bacteria tested in the study was 0.03 to >128 µg ml. Iclaprim exhibited synergy with sulfamethoxazole against 11 of the 16 bacterial strains tested, with mean fractional inhibitory concentration index (FICI) values of 0.2–0.5. Synergy with sulfamethoxazole was demonstrated against all Gram-positive bacteria and selected Gram-negative bacteria. Neither synergy nor antagonism was observed for combinations of iclaprim with ampicillin, meropenem, tetracycline, levofloxacin, aztreonam, piperacillin/tazobactam, colistin, cefepime or gentamicin against any of the bacterial strains tested. The significant reduction in the MIC values observed with the combination of iclaprim and sulfamethoxazole demonstrates that this regimen could be effective against common Gram-positive and selected Gram-negative respiratory bacteria.

Keyword(s): iclaprim , in vitro , pneumonia and synergy
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000027
2019-05-20
2020-01-26
Loading full text...

Full text loading...

/deliver/fulltext/acmi/1/3/acmi000027.html?itemId=/content/journal/acmi/10.1099/acmi.0.000027&mimeType=html&fmt=ahah

References

  1. Sader HS, Fritsche TR, Jones RN. Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates. Antimicrob Agents Chemother 2009;53:2171–2175 [CrossRef]
    [Google Scholar]
  2. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003;13:4217–4221 [CrossRef]
    [Google Scholar]
  3. Morrissey I, Maher K, Hawser S. Activity of iclaprim against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae. J Antimicrob Chemother 2009;63:413–414 [CrossRef]
    [Google Scholar]
  4. Laue H, Valensise T, Seguin A, Lociuro S, Islam K et al. In vitro bactericidal activity of iclaprim in human plasma. Antimicrob Agents Chemother 2009;53:4542–4544 [CrossRef]
    [Google Scholar]
  5. Bryant AE, Gomi S, Katahira E, Huang DB, Stevens DL. The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. J Med Microbiol 2019;68:456–466 [CrossRef]
    [Google Scholar]
  6. CLSI. M07–A10 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, approved standard: 10th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2015
    [Google Scholar]
  7. CLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing, informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2017
    [Google Scholar]
  8. Pillai SK, Moellering RC Jr, Eliopoulus GM.Antimicrobial Combinations In Lorian V. editor Antibiotics in Laboratory Medicine, 5th ed. Baltimore: Williams & Wilkins; 2005; pp365–440
    [Google Scholar]
  9. Laue H, Weiss L, Bernardi A, Hawser S, Lociuro S et al. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Chemother 2007;60:1391–1394 [CrossRef]
    [Google Scholar]
  10. Noviello S, Hawser S, Sader H, Huang DB. In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016. J Glob Antimicrob Resist 2019;16:236–238 [CrossRef]
    [Google Scholar]
  11. Andrews J, Honeybourne D, Ashby J, Jevons G, Fraise A et al. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J Antimicrob Chemother 2007;60:677–680 [CrossRef]
    [Google Scholar]
  12. Huang DB, File TM Jr, Torres A, Shorr AF, Wilcox MH et al. A phase II randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous Iclaprim versus vancomycin for the treatment of nosocomial pneumonia suspected or confirmed to be due to Gram-positive pathogens. Clin Ther 2017;39:1706–1718 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000027
Loading
/content/journal/acmi/10.1099/acmi.0.000027
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error